Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Ain Shams University100 enrolled

Overview

* The investigators evaluated the role of allopurinol in prevention of post-ERCP pancreatitis. * 100 Egyptian patients who were candidates for ERCP were included and divided into two groups. Group 1 (study group) included 50 patients who received two doses of allopurinol 300 mg each, 15 hours and 3 hours before ERCP and Group 2 (control group) included 50 patients who did not receive allopurinol prophylaxis.

A diagnosis of procedure-related pancreatitis was based on an increased serum amylase level greater than three times the upper normal limits, associated with abdominal pain requiring analgesics and persisting for at least 24 hours after the procedure.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

100

Conditions

Endoscopic Retrograde Cholangiopancreatography

Interventions

AllopurinolDRUG

600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who were going to be subjected to ERCP due to different causes Exclusion Criteria: * Patients with clinically evident acute pancreatitis or hyperamylesemia (≥150 IU/L) before the procedure. * Current or recent use of allopurinol (within the last 48 hours). * Hypersensitivity to allopurinol or hydro-soluble contrast solutions. * Current use of drugs with a known interaction with allopurinol, including cyclophosphamide, chlorpropamide, azathioprine, mercaptopurines, or probenecid. * NSAIDS intake within a week prior to assessment. * Previous endoscopic or surgical sphincterotomy. * Those with severe co-morbid conditions. * Female patients with a known or suspected pregnancy and/or lactation.

Outcomes

Primary Outcomes

Diagnosis of procedure-related pancreatitis

Time frame: At least 24 hours after the ERCP

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.